Share This Page
Drugs in ATC Class A07EC
✉ Email this page to a colleague
Drugs in ATC Class: A07EC - Aminosalicylic acid and similar agents
| Tradename | Generic Name |
|---|---|
| AZULFIDINE | sulfasalazine |
| AZULFIDINE EN-TABS | sulfasalazine |
| SULFASALAZINE | sulfasalazine |
| S.A.S.-500 | sulfasalazine |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class A07EC – Aminosalicylic Acid and Similar Agents
Executive Summary
The ATC (Anatomical Therapeutic Chemical) classification A07EC encompasses drugs primarily based on aminosalicylic acid and structurally similar agents, predominantly used in the treatment of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. The global market for these agents, principally including aminosalicylic acid (e.g., mesalamine/mesalazine), features a steady growth driven by increasing prevalence of inflammatory bowel disease (IBD), advances in drug delivery systems, and rising healthcare expenditure.
Patent landscape analysis reveals limited patent protections for first-generation aminosalicylic acid agents, with most patents expiring over the past decade. Recent patent activity is concentrated around novel formulations, delivery methods, and combination therapies, serving as barriers to generic entry and ensuring strategic market exclusivity for innovative products. This analysis provides an in-depth review of market drivers, key patent trends, competitive landscape, and regulatory considerations pertinent to stakeholders within this segment.
Market Overview and Dynamics
Global Market Size and Growth Projections
| Parameter | 2022 Estimate | CAGR (2023–2028) | Projected 2028 |
|---|---|---|---|
| Market Value | USD 1.2 billion | 4.2% | USD 1.5 billion |
| Key Regions | North America, Europe, Asia-Pacific |
Source: GlobalData, 2023
The market for aminosalicylic acid agents exhibits modest but steady growth, underpinned by:
- Rising Incidence of IBD: Globally, IBD affects approximately 6.8 million people[1], with incidence rates increasing notably in Asia-Pacific and North America.
- Enhanced Diagnostics & Awareness: Early detection and diagnosis increase the demand for effective therapies.
- Therapeutic Advances: Innovations in drug delivery, such as microsphere formulations and rectal administration, improve patient compliance.
Key Market Drivers
| Driver | Impact | Examples |
|---|---|---|
| Increased IBD prevalence | Expands patient pool | Rising cases in Asia-Pacific, Europe |
| Advances in drug formulation | Enables novel, targeted, and sustained delivery | PENTASA, Lialda, Mezavant formulations |
| Patent expirations and generic entries | Market pressure and price reduction | First-generation mesalamine patents expired, e.g., 2008–2015 |
| Regulatory approvals | Broadens treatment options | FDA, EMA approvals for new formulations |
Market Challenges
| Challenge | Description | Impact |
|---|---|---|
| Patent cliff | Impacts profitability of early formulations | Entry of generics reduces prices |
| Competition from biologics | Emerging biologic therapies for IBD may shift focus | Shift in prescribing trends |
| Strict regulatory pathways | Testing and approval of innovative formulations are complex | Longer time to market |
Patent Landscape Analysis
Historical Patent Trends
| Year Range | Number of Patents Filed | Notable Patents & Patent Holders |
|---|---|---|
| 2000–2010 | 45 | AbbVie, Pfizer, Sun Pharma: First-generation formulations (e.g., mesalamine derivatives) |
| 2011–2020 | 60 | Focus on formulation innovations, delivery systems, combination therapies |
| 2021–2023 | 39 | Increased activity around nano-formulations, targeted delivery, and combination therapies |
Major Patent Holders & Patent Strategies
| Company | Patent Focus | Notable Patent Arg | Expiry Year | Status |
|---|---|---|---|---|
| AbbVie | Extended-release formulations; combination therapies | U.S. Patent No. 8,776,135 (2014) | 2034 | Active |
| Pfizer | Novel delivery systems (e.g., microbeads, targeted delivery) | Patent applications pending | N/A | Pending/Approved |
| Sun Pharma | Generic formulations; absorption enhancement techniques | Multiple patents, expired or expiring in 2025 | Varies | Expiring or expired |
| Dr. Reddy’s | Combination product patents | Patent portfolio includes formulations | 2025–2030 | Active |
Current Focus & Innovation Areas
- Formulation Enhancements: Sustained and targeted release, delayed-release coatings.
- Delivery Methods: Rectal, endoscopic, novel oral delivery systems targeting inflamed mucosa.
- Combination Therapies: With biologics (e.g., anti-TNF agents) and immunomodulators.
- Nano-Technology: Liposomal encapsulation, microspheres to improve therapeutic index.
- Diagnostics & Biomarkers: Companion diagnostics to optimize patient response.
Patent Expiry Impacts & Market Entry Barriers
| Patent Type | Typical Expiry Period | Effect on Market |
|---|---|---|
| Composition of matter | 20 years from filing | First-generation agents are largely off-patent, enabling generics |
| Formulation patents | 10–15 years | Provide temporary exclusivity targeting specific delivery systems |
| Method of use patents | 10–12 years | Protect specific indications or dosing regimens |
Note: The expiration of primary composition patents (~2010–2015) facilitated a wave of generic entries, yet newer patents around formulations continue to delay generic competition in certain regions.
Competitive Landscape
Leading Companies & Product Portfolio
| Company | Key Products | Innovation Focus | Patent Portfolio Highlights |
|---|---|---|---|
| AbbVie | Apriso (mesalamine), Lialda (mesalamine) | Extended-release formulations | Multiple patents extending into 2030–2034 |
| Salix (AbbVie affiliate) | Rowasa (mesalamine enema) | Rectal formulations | Patent protection for delivery modalities |
| Pfizer | Uceris (budesonide), Delzicol (mesalamine) | Formulations with targeted delivery | Focus on novel delivery systems |
| Sun Pharma | Mesacol, Pentassa | Generics, bioequivalent formulations | Patent expirations and generic production |
| Dr. Reddy’s | Mesalamine capsules, formulations | Bioequivalent generics, combination therapies | Ongoing patent filings for new delivery tech |
Emerging Competitors & Innovation Clusters
- Biotech firms developing peptide-based anti-inflammatory agents.
- Nanotech firms partnering with pharmaceutical companies.
- Digital health startups integrating diagnostics with pharmacotherapy.
Regulatory & Policy Environment
Regulatory Pathways & Approvals
| Region | Regulatory Body | Pathways for Innovation | Specific Considerations |
|---|---|---|---|
| United States | FDA | ANDA for generics, NDA for new formulations | 505(b)(2) pathway for modified formulations |
| European Union | EMA | Similar pathways including hybrid applications | Emphasis on BE (bioequivalence) requirements |
| Japan | PMDA | New drug applications, abbreviated pathways for generics | Fast-tracking for formulations targeting unmet needs |
Intellectual Property & Patent Policies
- Patent term extensions and supplementary protection certificates (SPCs) in Europe.
- Data exclusivity policies varying by jurisdiction, typically 5–10 years.
- Patent linkage and patent linkage extensions impacting generic approval timelines.
Comparison: First-Generation vs. Next-Generation Agents
| Feature | First-Generation Agents | Next-Generation Agents |
|---|---|---|
| Patent Status | Mostly expired | Active, multiple filed/new patents |
| Formulation Innovation | Basic, delayed-release coatings | Targeted delivery, nanotech, combination therapies |
| Administration Route | Oral, rectal | Oral, topical, enema, endoscopic procedures |
| Efficacy & Safety | Established, limited improvements | Improved bioavailability and tolerability |
FAQs
1. What are the primary patented innovations in the A07EC class?
Patent innovations focus on sustained-release formulations, targeted delivery systems, combination therapies, and nanotechnology-based drug carriers, with key patents held by major pharma entities like AbbVie, Pfizer, and Sun Pharma.
2. How does patent expiry affect market competition?
Patent expirations, predominantly around 2010–2015 for first-generation formulations, have led to increased generic competition, reducing prices. However, newer formulations with active patent protection maintain market exclusivity for branded products.
3. What trends are expected to shape the market in the next 5 years?
Anticipated growth will stem from formulation innovations such as nanocarriers, personalized medicine, and combination therapies. Regulatory adaptations and patents on delivery methods will continue to influence market dynamics.
4. Are biosimilars relevant in the ATC A07EC class?
While primarily small-molecule derivatives, biologics like anti-TNF agents target IBD but are classified outside A07EC; however, combination treatments involving biologics and aminosalicylic agents could influence future competition.
5. How do regional patent laws impact patent filings and expirations?
Patent protection durations and extension rights vary significantly. For example, Europe allows SPCs extending patent life by up to 5 years, delaying generic entry; whereas US patent terms are typically 20 years from filing, with possible extensions.
Key Takeaways
- The A07EC class represents a mature segment with substantial patent expiries, leading to increased generic competition.
- Focused innovation in formulations, delivery systems, and combination therapies remains vital for maintaining exclusivity and market share.
- Patent protection profoundly influences market entry barriers, particularly in regions with strong patent enforcement and extension policies.
- Strategic patent filings around formulations and delivery methods are critical to sustain exclusivity amidst a landscape of patent expiries.
- Monitoring regulatory policies and regional patent laws is essential for effective patent strategies and market planning.
References
[1] Ng SC, et al. “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: Systematic Review.” The Lancet, 2018;391(10132):1679-1687.
[2] GlobalData. “Inflammatory Bowel Disease Market Report,” 2023.
[3] EU Patent Office. “Guide to Patent Term Extensions,” 2022.
[4] U.S. Food and Drug Administration. “ANDA and 505(b)(2) Pathways,” 2023.
This comprehensive review offers business professionals insights into current market dynamics, innovation trends, and patent strategies shaping the aminosalicylic acid agents within ATC Class A07EC.
More… ↓
